GCM
VKTX icon

Graham Capital Management’s Viking Therapeutics VKTX Stock Holding History

Graham Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$863K Buy
+22,114
New +$714K 0.02% 553
2025
Q4 		– Sell
-21,080
Closed -$554K – 1604
2025
Q3 		$554K Buy
+21,080
New +$629K 0.01% 576
2022
Q2 		– Sell
-127,070
Closed -$381K – 1257
2022
Q1 		$381K Buy
127,070
+75,279
+145% +$270K 0.01% 649
2021
Q4 		$238K Buy
+51,791
New +$290K 0.01% 402

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Graham Capital Management's VKTX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 22,114 shares worth $863K. The stake represents 0.02% of the portfolio and ranks #553 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in VKTX as recently as Q3 2025.

Graham Capital Management first reported a position in VKTX in Q4 2021 and has held it in 4 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Graham Capital Management held 22,114 shares of Viking Therapeutics worth $863K as of Q2 2026.
  • Viking Therapeutics was a new Graham Capital Management position in Q2 2026.
  • Viking Therapeutics made up 0.02% of Graham Capital Management's portfolio in Q2 2026, its #553 holding.
  • Graham Capital Management first reported a position in Viking Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.